Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations—a meta-analysis
Vuong H, Altibi A, Duong U, Ngo H, Pham T, Tran H, Oishi N, Mochizuki K, Nakazawa T, Hassell L, Katoh R, Kondo T. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations—a meta-analysis. Tumor Biology 2017, 39: 1010428317713913. PMID: 29037127, DOI: 10.1177/1010428317713913.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerTERT promoter mutationsDistant metastasisThyroid cancerPromoter mutationsRET/PTC rearrangementsBRAF mutationsPresence of distant metastasesAssessment of patient prognosisTumor risk stratificationAssociated with distant metastasisPapillary thyroid carcinomaMeta-analysisPredicting distant metastasisAssociation of BRAFRandom-effects modelThyroid carcinomaTERT promoterRisk stratificationPatient prognosisRAS mutationsAdverse outcomesMetastasisIncreased riskBRAFTERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—A meta-analysis of aggregate data
Vuong H, Altibi A, Duong U, Ngo H, Pham T, Chan A, Park C, Fung K, Hassell L. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—A meta-analysis of aggregate data. Critical Reviews In Oncology/Hematology 2017, 120: 1-9. PMID: 29198322, DOI: 10.1016/j.critrevonc.2017.09.013.Peer-Reviewed Original ResearchMeSH KeywordsBrain NeoplasmsDisease-Free SurvivalGliomaHumansIsocitrate DehydrogenaseMutationNeoplasm GradingPrognosisPromoter Regions, GeneticTelomeraseConceptsTelomerase reverse transcriptase promoter mutationTelomerase reverse transcriptaseIsocitrate dehydrogenase mutation statusProgression-free survivalTERT promoter mutationsIsocitrate dehydrogenase mutationPromoter mutationsIDH-mutantGlioma patientsOverall survivalTumor gradeMutation statusTelomerase reverse transcriptase mutationsAssociated with reduced OSGrade II/III tumorsWHO grade IIMeta-analysisIDH-wild typeInverse variance methodRandom-effects modelII/III tumorsTERT-mutIII tumorsPrognostic factorsPrognostic valuePrognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta‐analysis
Vuong H, Altibi A, Duong U, Hassell L. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta‐analysis. Clinical Endocrinology 2017, 87: 411-417. PMID: 28666074, DOI: 10.1111/cen.13413.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, PapillaryHumansMutationPrognosisPromoter Regions, GeneticProto-Oncogene Proteins B-rafRisk AssessmentTelomeraseThyroid Cancer, PapillaryThyroid NeoplasmsConceptsTERT promoter mutationsPapillary thyroid carcinomaPromoter mutationsRisk stratificationRisk stratification of papillary thyroid carcinomaAssociated with increased tumor aggressivenessManagement of papillary thyroid carcinomaGroup of papillary thyroid carcinomasPapillary thyroid carcinoma patientsPooled estimates of odds ratiosCombination of BRAFEstimates of odds ratiosRandom-effects modelCoexisting BRAFThyroid carcinomaPrognostic implicationsTumor aggressivenessClinicopathological implicationsBRAFClinical managementConcurrent BRAFRisk groupsOdds ratioVirtual Health LibraryWeb of Science